Drug Trial Radar · NCT05673239
Effects of L-carnitine Therapy on the Heart of Maintenance Hemodialysis Patients
Last checked: Nov 19, 2026Latest source record: Aug 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,008
Actual
Start
Jan 15, 2023
Primary completion
Jun 30, 2023
Study completion Jun 30, 2024
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Zhejiang Chinese Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is intended to be a multicenter, prospective, non-randomized, controlled real-world study. Patients receiving L-carnitine injection were included in the experimental group and the control group according to whether they received L-carnitine injection. Patients receiving L-carnitine injection were included in the experimental group, and those receiving L-carnitine injection were included in the control group.To observe the effects of L-carnitine on cardiac function in hemodialysis patients.
Conditions
- Renal Dialysis
Interventions
Levocarnitine InjectionDrug
The patients in the test group were injected with 1-2g (10-20mg/kg) levocarnitine on each dialysis day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Left ventricular ejection fractionTime frame: baseline and week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.